The Beatrice Hunter Cancer Research Institute logo
  • Dr. Pier Jr Morin, PhD, MBA


Assistant Professor – Biochemistry, Department of Chemistry and Biochemistry, Université de Moncton; Adjunct Professor – Biochemistry, Department of Biochemistry, Université de Sherbrooke                            


Université de Moncton (primary)
Université de Sherbrooke (cross-appointment)

Research Interests:

Cellular signaling, kinases, brain tumours, glioblastomas

Targeting the kinome in glioblastomas

Glioblastoma multiforme (GBM) is an aggressive brain tumor for which current therapeutic approaches are limited.  Dr. Morin and his research team focus on the identification of hyperactivated signaling pathways involved in the biogenesis and development of GBMs and which could serve as sites for targeted therapeutic intervention.  Differentially regulated protein kinases, key mediators of signal transduction and druggable targets, are characterized in primary GBM tumours and cell lines.

Membership Status:

Dr. Morin is a BHCRI Associate Member.


(506) 858-4355



Rémi Rossignol building, Université de Moncton, 18 Antonine-Maillet avenue, Moncton, New Brunswick, Canada, E1A 3E9


Patterson, A.E., Miller, J.J., Miles, B.A., Stewart, E.L., Melanson, E.J., Vogels, C.M., Cockshutt, A.M., Decken, A., Morin, P. Jr. et Westcott, S.A. (2014) Synthesis, characterization and anticancer properties of (salicylaldiminato)platinum(II) complexes. Inorganica Chim. Acta. 415 : 88-94.

Lang-Ouellette, D. et Morin, P. Jr. (2014) Differential expression of miRNAs with metabolic implications in hibernating thirteen-lined ground squirrels, Ictidomys tridecemlineatus. Mol. Cell. Biochem. 394: 291-298.   

St-Coeur, P-D, Touaibia, M., Cuperlovic-Culf, M. et Morin, P. Jr. (2013) Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas. Genomics, Proteomics & Bioinformatics. 11: 199-206.

Morin, P. Jr., Ferguson, D., LeBlanc, L., Hébert, M., Paré, A., Jean-François, J., Surette, M., Touaibia, M. et Cuperlovic-Culf, M. (2013) NMR metabolomics analysis of the effects of 5-lipoxygenase inhibitors on metabolism in glioblastomas. J. Proteome Res. 12: 2165-2176.

Cuperlovic-Culf, M., Culf, A.S., Morin, P. Jr. et Touaibia, M. (2013) Application of metabolomics in drug discovery, development and theranostics. Curr. Metabol. 1: 41-57.

Lyons, P.J., Poitras, J.J., Courteau, L.A., Storey, K.B. et Morin, P. Jr. (2013) Identification of differentially regulated microRNAs in cold-hardy insects. Cryo Letters. 34: 83-89.

St-Coeur, P-D, Ferguson, D., Morin, P. Jr. et Touaibia, M. (2013) PF-8380 and closely related analogues synthesis, structure-activity relationship towards autotaxin inhibition and glioma cell viability. Archiv. Pharm. Chem. Life Sci. 346: 91-97.

Wang, Y., Moncayo, G., Morin, P. Jr., Xue, G., Grzmil, M., Lino, M.M., Clément-Schatlo, V., Frank, S., Merlo, A et Hemmings, B.A. (2013) Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene. 32:872-882.

Cuperlovic-Culf, M., Ferguson, D., Culf, A., Morin, P. Jr. et Touaibia, M. (2012) 1H NMR metabolomics analysis of glioblastoma subtypes: correlation between metabolomics and gene expression characteristics. J. Biol. Chem. 287: 20164-20175.

Lefort, N., Morin, P. Jr. et Cuperlovic-Culf, M. “Analysis and modeling of metabolism of cancer. In: Biomechanics of cells and tissues: experiments, models and simulations”. Springer, New York, 2012.

Site by: Spectacle Group